Notable Thursday Option Activity: DKNG, WMT, AQST

Walmart (WMT) options traded 118,504 contracts today (~11.9M underlying shares), equal to about 61.2% of its one‑month average daily volume (19.4M shares), with notable concentration in the $90 put expiring Jan 16, 2026 (17,935 contracts, ~1.8M shares). Aquestive Therapeutics (AQST) saw 13,296 option contracts (~1.3M underlying shares, ~54.3% of its ADTV of 2.4M), led by the $11 call expiring Feb 20, 2026 (5,140 contracts, ~514k shares); these large relative flows suggest concentrated directional positioning or hedging interest but do not by themselves imply a change to fundamentals.

Analysis

Market structure: The concentrated WMT flow (17,935 Jan‑16‑2026 $90 puts ≈1.8M shares) signals heavy demand for long‑dated downside protection or large directional bearish bets; market‑makers and liquidity providers are the immediate beneficiaries via elevated IV and spread capture, while short‑tenor retail longs may face amplified intraday moves. AQST’s Feb‑20‑2026 $11 call block (5,140 contracts ≈514k shares) reads as speculative upside accumulation or sponsor-driven positioning in a small‑cap biotech; sector peers (XBI constituents) will see correlated vol repricing. Cross‑asset: expect modest lift in single‑stock implied vol (WMT, AQST), transient flow into equity financing and hedging that can slightly widen corporate credit spreads in retail names; macro FX and commodities impact is negligible.

Risk assessment: Tail risks include a pronounced consumer demand shock (worse‑than‑expected CPI or holiday sales) that would push WMT equity and retail peers down >10% in weeks, and an adverse clinical/regulatory outcome for AQST that could wipe out speculative premium. Immediate (days): higher realized vol and directional squeezes; short (weeks–months): option expiries and earnings/CPI will be decisive; long (quarters–years): secular retail share shifts and AQST binary outcomes dominate. Hidden dependencies: flows may be hedges for large stock positions, index rebalancing, or acquisition arbitrage — monitor 13F, block trades, and dark pool prints. Key catalysts: WMT quarterly sales/comp commentary, US retail data, CPI prints, and AQST trial/filing updates.

Trade implications: For WMT favor defined‑risk, income‑oriented entry: sell Jan‑16‑2026 $90/$85 put spreads (target credit ≥$1.00, position size 1–2% notional) to monetize elevated put demand while capping downside to ~5% width; alternatively, if worried about drawdown, buy Jan‑2026 $90 puts as 0.5–1% hedge. For AQST, take a selective long‑vol stance: buy Feb‑20‑2026 $11/$15 call verticals (limit cost to <$2.50, position 0.5–1%) or small outright call LEAP purchases if clinical catalysts are imminent. Pair idea: long AQST calls vs short XBI (size to neutralize beta) to isolate idiosyncratic upside.

Key Decisions for Investors

• Establish a 1–2% notional bullish income trade in WMT: sell the Jan‑16‑2026 $90/$85 put spread (target credit ≥$1.00) to capture elevated put demand while limiting downside to the $85 strike; close or roll if WMT trades below $84 within 3 months.
• If you own WMT stock >1% weighting, add a 0.5–1% hedge by buying Jan‑2026 $90 puts (or equivalent collar) to cap downside through the Jan 2026 options expiry ahead of Q4 earnings and CPI windows.
• Speculative long in AQST: purchase Feb‑20‑2026 $11/$15 call verticals sized 0.5–1% of portfolio, limiting max loss to the premium (target cost <$2.50), and set a trailing stop to take profits at +50–100% or cut at −50%.
• Relative‑value pair: go long AQST call exposure vs short XBI futures/ETF sized to neutralize sector beta (initiate within 1–2 weeks); this isolates AQST idiosyncratic upside vs broad biotech drag from a negative trial environment.